Data Year:

For its 2025 fiscal year, PEDIATRIX MEDICAL GROUP INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Healthcare industry
Mark S. Ordan
Chief Executive Officer, Director
Total Compensation $14,140,217 View details Pay Rank By Title In Healthcare industry #16 View more
Mary Ann E. Moore
Executive Vice President, General Counsel, Chief Administrative Officer and Secretary
Total Compensation $3,031,152 View details Pay Rank By Title In Healthcare industry #6 View more
James D. Swift M.D.
Former Chief Executive Officer
Total Compensation $2,775,881 View details Pay Rank By Title In Healthcare industry #54 View more
Kasandra H. Rossi
Executive Vice President, Chief Financial Officer & Treasurer
Total Compensation $1,860,037 View details Pay Rank By Title In Healthcare industry #42 View more
Don Gregory Neeb
Executive Vice President, Chief Investment & Strategy Officer
Total Compensation $5,317,268 View details Pay Rank By Title In Healthcare industry #4 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at PEDIATRIX MEDICAL GROUP INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. PEDIATRIX MEDICAL GROUP INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. PEDIATRIX MEDICAL GROUP INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mark S. Ordan
Chief Executive Officer, Director
Total Cash $5,670,014 Equity $8,456,024 Other $14,179 $14,140,217
Mary Ann E. Moore
Executive Vice President, General Counsel, Chief Administrative Officer and Secretary
Total Cash $1,625,000 Equity $1,391,936 Other $14,216 $3,031,152
James D. Swift M.D.
Former Chief Executive Officer
Total Cash $123,148 Equity $730,720 Other $1,922,013 $2,775,881
Kasandra H. Rossi
Executive Vice President, Chief Financial Officer & Treasurer
Total Cash $1,247,500 Equity $598,276 Other $14,261 $1,860,037
Don Gregory Neeb
Executive Vice President, Chief Investment & Strategy Officer
Total Cash $1,747,900 Equity $3,569,243 Other $125 $5,317,268
For its 2025 fiscal year, PEDIATRIX MEDICAL GROUP INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Mark S. Ordan CEO Pay $14,170,209 Median Employee Pay $155,070 CEO Pay Ratio 91:1
For its 2025 fiscal year, PEDIATRIX MEDICAL GROUP INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Guy P. Sansone Total Cash $311,673
John M. Starcher, Jr. Total Cash $255,006
Kurt D. Newman, M.D. Total Cash $188,102
Laura A. Linynsky Total Cash $255,006
Mark S. Ordan Total Cash $34,134
Michael A. Rucker Total Cash $269,173
Shirley A. Weis Total Cash $273,339
Sylvia J. Young Total Cash $255,006
Thomas A. McEachin Total Cash $282,506
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.